Recent Finacing
Recent Raise
Phoenix PharmaLabs develops non-addictive opioid/NOP partial-agonist therapeutics—lead candidates PPL-103 and PPL-138—for acute and chronic pain and substance-use disorders, advancing them from preclinical toward clinical trials.
